$109.07 +4.17 (%) Alnylam Pharmaceuticals Inc - NASDAQ

Aug. 28, 2015 | 04:00 PM

Partner Headlines

  1. 4 Biotechs Piper Jaffray Is Buying On The Pullback

    Benzinga | Aug. 26, 2015 | 15:27PM EST
  2. Here's One Biotech Stock JMP Analysts Are Very Bullish On

    Benzinga | Aug. 26, 2015 | 09:31AM EST
  3. Benzinga's Top Initiations

    Benzinga | Aug. 11, 2015 | 09:45AM EST
  4. Benzinga's Top Downgrades

    Benzinga | Aug. 7, 2015 | 09:34AM EST
  5. 5 Biotech Stocks On Deck With The FDA

    Benzinga | Jun. 30, 2015 | 13:39PM EST
  6. Julian Robertson Adds 16 New Stakes to Portfolio

    GuruFocus | Jun. 23, 2015 | 18:39PM EST
  7. Gurus Purchase Tekmira Pharmaceuticals in Q1

    GuruFocus | Jun. 19, 2015 | 17:57PM EST
  8. JMP Sees A 'Negative Market Tone' In Biotechnology

    Benzinga | Jun. 15, 2015 | 13:31PM EST
  9. Alnylam Reports Data on Potential Alexion Rival Drug

    IBD | Jun. 12, 2015 | 12:38PM EST
  10. US Stock Futures Slide Ahead Of Economic Data

    Benzinga | Jun. 12, 2015 | 07:22AM EST
  11. Alnylam Reports Positive Initial Clinical Results for ALN-CC5, an Investigational RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases

    Benzinga | Jun. 12, 2015 | 06:05AM EST
  12. After-Hours Movers Friday: Seventy Seven Energy, Kite Pharma

    Benzinga | May. 16, 2015 | 09:50AM EST
  13. Alnylam Pharmaceuticals

    IBD | Apr. 21, 2015 | 18:48PM EST
  14. Alnylam Says Neurological Drug Passes Midstage Study

    IBD | Apr. 21, 2015 | 13:22PM EST
  15. Morning Market Gainers

    Benzinga | Apr. 21, 2015 | 09:45AM EST
  16. Benzinga's Top #PreMarket Gainers

    Benzinga | Apr. 21, 2015 | 08:13AM EST
  17. CAR-T Therapy Stocks Hit Hard Following AACR Data

    Benzinga | Apr. 20, 2015 | 13:44PM EST
  18. It's A Big Weekend For Biotech

    Benzinga | Apr. 17, 2015 | 16:31PM EST
  19. Alnylam and Collaborators Publish Pre-clinical Study Results in Nature Medicine on ALN-AT3

    Benzinga | Apr. 13, 2015 | 11:01AM EST
  20. Benzinga's Top Initiations

    Benzinga | Feb. 27, 2015 | 09:29AM EST
  21. Microsoft, Bank Of New York And Others Insiders Have Been Buying

    Benzinga | Feb. 2, 2015 | 08:57AM EST
  22. Deutsche Bank's Top Biotech Picks For 2015

    Benzinga | Jan. 22, 2015 | 11:09AM EST
  23. Mid-Afternoon Market Update: Alnylam Pharmaceuticals Drops Following Equity Offering; Insperity Shares Spike Higher

    Benzinga | Jan. 21, 2015 | 15:10PM EST
  24. 4 More Biotech Secondaries Traders Are Watching

    Benzinga | Jan. 21, 2015 | 13:38PM EST
  25. Mid-Day Market Update: U.S. Stocks Surge; Netflix Shares Jump On Upbeat Earnings

    Benzinga | Jan. 21, 2015 | 12:53PM EST
  26. Mid-Morning Market Update: Markets Mixed; UnitedHealth Profit Tops Expectations

    Benzinga | Jan. 21, 2015 | 10:42AM EST
  27. Shares Of Alnylam Pharmaceuticals Lower Following Equity Offering

    Benzinga | Jan. 21, 2015 | 10:03AM EST
  28. Morning Market Losers

    Benzinga | Jan. 21, 2015 | 09:55AM EST
  29. Wednesday Morning Movers: Netflix Flying High

    Benzinga | Jan. 21, 2015 | 08:55AM EST
  30. Alnylam Pharmaceuticals

    IBD | Jan. 20, 2015 | 18:44PM EST
  31. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

    Benzinga | Jan. 12, 2015 | 08:55AM EST
  32. Alnylam Files Clinical Trial Application to Initiate a Phase 1 Study for ALN-AS1, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias

    Benzinga | Jan. 5, 2015 | 08:02AM EST
  33. Mid-Day Market Update: McDonald's Drops On Weak November Sales; Acceleron Pharma Shares Jump

    Benzinga | Dec. 8, 2014 | 12:56PM EST
  34. Mid-Morning Market Update: Markets Mixed; Merck To Buy Cubist Pharmaceuticals For $102/Share

    Benzinga | Dec. 8, 2014 | 10:46AM EST
  35. Alnylam jumps on trial results

    IBD | Oct. 13, 2014 | 18:46PM EST
  36. U.S. Stocks Fluctuate; Shutterfly Shares Decline On Aborted Merger Talks

    Benzinga | Oct. 13, 2014 | 15:18PM EST
  37. Alnylam Drug Scores Against Rare Nerve Disease

    IBD | Oct. 13, 2014 | 13:59PM EST
  38. Midday Gainers From October 13 - Doral Financial, Nanosphere, Ibio, Atlas Energy

    Benzinga | Oct. 13, 2014 | 13:55PM EST
  39. Lithia Motors Dips On Lowered Earnings Forecast; CSX Shares Gain

    Benzinga | Oct. 13, 2014 | 12:30PM EST
  40. Markets Down; Targa To Acquire Atlas Pipeline, Atlas Energy

    Benzinga | Oct. 13, 2014 | 11:05AM EST
  41. Benzinga's Volume Movers

    Benzinga | Oct. 13, 2014 | 10:12AM EST
  42. Morning Market Movers

    Benzinga | Oct. 13, 2014 | 09:39AM EST
  43. Alnylam Broadens Pipeline With ALN-AGT, A Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen For The Treatment Of Hypertensive Disorders Of Pregnancy, Including Preeclampsia

    Benzinga | Sep. 12, 2014 | 08:02AM EST
  44. The Biotech Stock With The Biggest Head Of Steam

    Benzinga | Aug. 4, 2014 | 14:35PM EST
  45. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD | Jun. 30, 2014 | 17:00PM EST
  46. Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

    Benzinga | Jun. 23, 2014 | 18:25PM EST
  47. Alnylam Pharma

    IBD | May. 12, 2014 | 18:42PM EST
  48. Alnylam Presents Pre-Clinical Data on RNAi Therapeutics at ISA

    Benzinga | Apr. 29, 2014 | 08:02AM EST
  49. UPDATE: Alnylam, Collaborators to Offer New Clinical Data for Patisiran

    Benzinga | Apr. 28, 2014 | 08:02AM EST
  50. UPDATE: Alnylam Receives Positive Opinion for Orphan Drug Designation in EU for ALN-TTRsc

    Benzinga | Apr. 2, 2014 | 08:05AM EST
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!